

Click for Full Prescribing Information for [Dobutamine in 5% Dextrose Injection, USP](#) and [Dobutamine Injection, USP](#), including **BOXED WARNING** if applicable.



**Pfizer Inc.**  
275 North Field Drive  
Lake Forest, IL 60045

August 1, 2022

**Notification of Emergency Date Extension for Dobutamine in 5% Dextrose Injection, USP Flexible Container and Dobutamine Injection, USP Single Dose Vial, Multiple Presentations**

Dear Customer,

Pfizer has received approval from the U.S. Food and Drug Administration (FDA) of our emergency request to extend the use date of 5 lots of **Dobutamine in 5% Dextrose Injection, USP Flexible Container** and 6 lots of **Dobutamine Injection, USP Single Dose Vial**, totaling 11 lots, to mitigate a shortage of these medically necessary products.

Depending on the presentation, the lots listed in the table included at the end of this letter have been extended by four to six months past their labeled expiration date. The FDA is not requiring or recommending that the lots identified in the table be relabeled with new extended use dates. If replacement product becomes available during the extension period, customers are expected to replace and properly dispose of these affected lots as soon as possible. We anticipate that FDA's [website](#), which lists extended use dates to assist with drug shortages, will also be updated to reflect this information.

If you have any questions, please call our Customer Service Department at 1-844-646-4398.

Thank you,

Angelika Piatek  
Portfolio Director, Premix, Specialty Solutions,  
& Micronutrients  
Pfizer Hospital U.S.

Linna Wilkins  
Portfolio Director, Cardiovascular &  
Steroids  
Pfizer Hospital U.S.

**Emergency Extended Use Dating for 5 Lots of Dobutamine in 5% Dextrose Injection, USP Flexible Container and 6 Lots of Dobutamine Injection, USP Single Dose Vial**

Unit of Sale NDC	Unit of Use NDC	Product Description	Lot Number	Labeled Expiration Date	New Extended Use Date
00409-2346-32	00409-2346-31	Dobutamine in 5% Dextrose Injection, USP 250 mg/250 mL (1 mg/mL) Flexible Container	25505KL00	7/1/2022	<b>1/1/2023</b>
00409-2347-32	00409-2347-31	Dobutamine in 5% Dextrose Injection, USP 500 mg/250 mL (2 mg/mL) Flexible Container	26607KL00	8/1/2022	<b>12/1/2022</b>
00409-3724-32	00409-3724-11	Dobutamine in 5% Dextrose Injection, USP 1,000 mg/250 mL (4 mg/mL) Flexible Container	24405KL00	6/1/2022	<b>12/1/2022</b>
			25509KL00	7/1/2022	<b>1/1/2023</b>
			25503KL00		
00409-2344-01	00409-2344-01	Dobutamine Injection, USP 250 mg/20 mL (12.5 mg/mL) Single Dose Glass Fliptop Vial	17302DK00	5/1/2022	<b>11/1/2022</b>
			24115DK00	12/1/2022	<b>6/1/2023</b>
00409-2344-02	00409-2344-62	Dobutamine Injection, USP 250 mg/20 mL (12.5 mg/mL) Single Dose Glass Fliptop Vial	17301DK00	5/1/2022	<b>11/1/2022</b>
			19167DK00	7/1/2022	<b>1/1/2023</b>
			20162DK00	8/1/2022	<b>2/1/2023</b>
			24110DK00	12/1/2022	<b>6/1/2023</b>